Navigation Links
MiddleBrook Pharmaceuticals Hires Key Commercial Team Members

Company prepares to launch Moxatag(TM), the first and only FDA-approved once-daily amoxicillin, in the first quarter of 2009

GERMANTOWN, Md., Nov. 19 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), today announced it has hired the following key commercial team members:

  • Frank L. Koos has joined MiddleBrook Pharmaceuticals as senior vice president, sales & business development. Koos brings nearly 20 years' experience in sales and sales management to his role at MiddleBrook. Prior to joining MiddleBrook, Koos served as vice president of professional sales for Adams Respiratory Therapeutics(R) (Adams). Prior to Adams, Koos held successive leadership roles including vice president of sales for PharMetrics and group director, sales and service at IMS Health. Previously, Koos was a sales representative and a sales trainer for the Ortho Pharmaceutical division of Johnson and Johnson, and he served as a lieutenant in the United States Army.

  • Salvatore A. Buscema has joined MiddleBrook Pharmaceuticals as vice president, sales. Prior to joining MiddleBrook, Buscema held multiple roles of increasing responsibility at Adams where he led two sales force expansions, directed a comprehensive sales force automation project and facilitated trade sales. The Adams field sales teams under Buscema's leadership grew sales from $20 million to over $400 million annually. Buscema began his sales career at IMS Health where his key accounts included Johnson and Johnson and AstraZeneca.

  • Sheila Filipponi has joined MiddleBrook Pharmaceuticals as vice president, trade sales. Filipponi brings over 20 years of sales and sales management experience to MiddleBrook. Prior to joining MiddleBrook, Filipponi was executive director, trade sales at Adams where she was responsible for managing national drug customer accounts. Previously, Filipponi held successive leadership roles in sales management at the Consumer Health division of Novartis, including national account manager and business development manager. Prior to that, she held various positions in sales management at the McNeil Consumer Products division of Johnson and Johnson, including district management and sales training roles.

  • Ronald E. Hunt has joined MiddleBrook Pharmaceuticals as associate vice president, sales training and incentives. Prior to joining MiddleBrook, Hunt served as director, field sales training at Reckitt Benckiser(R). Previously, he held key positions in sales, sales management and sales operations at Adams, Aventis Pharmaceuticals, Inc. and Aventis' legacy companies.

  • Sonya Sharp-Stenken has joined MiddleBrook Pharmaceuticals as associate vice president, managed markets. Prior to joining MiddleBrook, Sharp-Stenken was director of national accounts for the Eastern United States with Reckitt Benckiser(R). Previously, she held the position of executive director, managed markets at Adams. Sharp-Stenken has spent over 12 years in the pharmaceutical industry and brings both small and large manufacturer experience from her time with leading companies such as Muro Pharmaceutical and AstraZeneca. She has held multiple sales, marketing, and managed care positions.

John Thievon, MiddleBrook president and CEO, said, "With the addition of Frank, Sal, Sheila, Ron and Sonya, our commercial leadership team is now fully in place. I am extremely pleased that we have been able to attract these talented professionals to MiddleBrook. They have worked together before, and their common background of success will enable them to quickly execute our plan to hire our national field force representatives, begin sales training and prepare for the launch of Moxatag, the first and only FDA-approved once-daily amoxicillin."

About Moxatag:

Moxatag (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of Moxatag are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. Moxatag is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about Moxatag, please visit

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We are currently developing a portfolio of anti-infective products utilizing our proprietary, once-a-day pulsatile delivery technology called Pulsys. Our near-term corporate strategy is to improve dosing regimens and/or frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit

Forward-Looking Statements:

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential, " "estimate," "will," "may," "predict," "should, " "could," "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2008, our Annual Report on Form 10-K for the year ended Dec. 31, 2007, and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., Pulsys, Moxatag and Keflex are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademark applications. Each of the other trademarks, tradenames or services marks appearing in this document belongs to its respective holder.

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
5. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. MiddleBrook Hires TalenTactics to Recruit National Field Force
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... and partnering meetings taking place in the month of ... – Partnering Forum RepliCel will be presenting at ... Meeting on the Mesa to be held October 7-9 ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... (PRWEB) , ... October 07, 2015 , ... Neil Riordan, ... Beach Anti-Aging Summit Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. ... adult stem cell therapy. , He is the Co-Founder and Chief Science ...
(Date:10/7/2015)... --  PDI , a leader in infection prevention products ... challenges across various healthcare settings, as well as guidelines ... tool is part of a larger effort to raise ... and lower healthcare-associated infections. ... how to use the right product, in the right ...
Breaking Biology Technology:
... 9, 2011) The brain is a black box. ... much like the inner workings of a computer chip. ... economy of an assembly line, neural circuits are impenetrable ... Department of Neurobiology have developed a technique for unraveling ...
... of Standards and Technology (NIST),have demonstrated an ... mechanical component 1,000 times,more vigorously than ever ... a new tool for processing,information and potentially ... object at the,smallest possible, or quantum, scale. ...
... NEW YORK, March 9, 2011 ... is available in its catalogue: ... and Market Forecasts to 2017 ... Retinopathy Therapeutics - Pipeline Assessment and Market ...
Cached Biology Technology:
(Date:10/7/2015)... , October 8, 2015 ... revenues for Fingerprint Cards (FPC) during third quarter 2015 amounted ... guidance of around 860 MSEK that was communicated 20 August ... a further strengthened delivery capacity and a continued growing demand ... 2015 is estimated to be higher than during the third ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... The Proceedings of the National Academy of Science ... Medicine generated a mouse model exhibiting reduced inflammation. ... transcription factor LITAF (Lipopolysaccharide [LPS]-Induced TNF-Alpha Factor) controls ... better known and studied NF-kB transcriptional regulator. ...
... for insects and other small terrestrial animals by firing ... the water's surface. These water shots were once thought ... discovered new levels of sophistication in the archerfish's hunting ... behavior has evolved. The findings are reported by Thomas ...
... at the University of Rochester may have answered one ... our neurons, which are responsible for our crystal-clear thoughts, ... the November issue of Nature Neuroscience, the Rochester study ... "noisy," signals to represent the ambiguities of the real ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: